Core Scientific (CORZ) legal chief sells 10,000 shares under 10b5-1 plan
Rhea-AI Filing Summary
Todd M. Duchene, Chief Legal and Administrative Officer of Core Scientific, sold 10,000 shares of Common Stock on July 20, 2026, at a weighted average price of $22.2995 per share, with sale prices ranging from $21.99 to $22.71.
Following this transaction, he directly holds 1,999,101 shares of Core Scientific Common Stock. The sale was effected under a Rule 10b5-1 trading plan adopted on December 5, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 10,000 shares
Net Sell
1 txn
Insider
DUCHENE TODD M
Role
See remarks
Sold
10,000 shs ($223K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 10,000 | $22.2995 | $223K |
Holdings After Transaction:
Common Stock — 1,999,101 shares (Direct)
Footnotes (2)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
- F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.99 to $22.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
Key Figures
Shares sold: 10,000 shares
Average sale price: $22.2995 per share
Sale price range: $21.99–$22.71 per share
+2 more
5 metrics
Shares sold
10,000 shares
Common Stock sale by Todd M. Duchene on July 20, 2026
Average sale price
$22.2995 per share
Weighted average price for the 10,000-share sale
Sale price range
$21.99–$22.71 per share
Range of prices at which the shares were sold
Shares owned after sale
1,999,101 shares
Direct Common Stock holdings after the reported sale
Net shares sold
10,000 shares
Net change in direct holdings from this transaction
Key Terms
Rule 10b5-1 trading plan, weighted average price, Sale in open market or private transaction
3 terms
Rule 10b5-1 trading plan regulatory
"transactions were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Sale in open market or private transaction financial
"transaction code description: Sale in open market or private transaction"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did CORZ report for Todd M. Duchene?
Core Scientific (CORZ) reported that Todd M. Duchene sold 10,000 shares of Common Stock on July 20, 2026. The sale was classified as a sale in open market or private transaction and left him with 1,999,101 shares held directly.
Was the CORZ insider sale made under a Rule 10b5-1 trading plan?
Yes. The sale of 10,000 Core Scientific (CORZ) shares was effected under a Rule 10b5-1 trading plan. A footnote states the plan was adopted on December 5, 2025, and the Form 4 indicates the Rule 10b5-1 checkbox as affirmed.
What is Todd M. Duchene’s role at Core Scientific (CORZ)?
Todd M. Duchene serves as Core Scientific’s Chief Legal and Administrative Officer. This officer role is noted in the filing remarks, and he is identified as an officer but not a director or 10% beneficial owner in the insider ownership details.